By Counterforce Health Team in Koselugo (selumetinib) —

How to Get Koselugo (Selumetinib) Covered by Blue Cross Blue Shield in California: Prior Authorization Guide and Appeal Scripts

Answer Box: Getting Koselugo Covered by Blue Cross Blue Shield in California

Koselugo (selumetinib) requires prior authorization from Blue Cross Blue Shield in California but is generally covered when FDA criteria are met. The fastest path: 1) Gather NF1 diagnosis, imaging showing inoperable plexiform neurofibromas, and baseline cardiac/eye exams, 2) Submit PA through Blue Shield's provider portal with complete documentation, 3) If denied, file internal appeal within 30 days, then request Independent Medical Review (IMR) through California's DMHC. Success rates for specialty drug appeals are around 10-11% at IMR level.

First step today: Contact Blue Shield at (888) 266-8080 to confirm current formulary status and PA requirements for your specific plan.

Table of Contents

  1. When Alternatives Make Sense
  2. Current Treatment Options for Pediatric NF1
  3. Blue Cross Blue Shield Coverage Requirements
  4. Step-by-Step: Fastest Path to Approval
  5. Exception Strategy for Non-Formulary Status
  6. Appeals Playbook for California
  7. Common Denial Reasons & Solutions
  8. Costs & Patient Support Programs
  9. FAQ

When Alternatives Make Sense

For pediatric patients with neurofibromatosis type 1 (NF1) and symptomatic plexiform neurofibromas, Koselugo remains the gold standard, but alternatives may be considered when:

  • Initial denial occurs and you need coverage while appealing
  • Patient experiences intolerable side effects (cardiomyopathy, severe skin reactions)
  • Age restrictions apply (some plans limit to specific pediatric age ranges)
  • New FDA approvals become available on preferred formularies
Note: Unlike many specialty medications, NF1 plexiform neurofibromas have limited treatment options, making Koselugo particularly important to pursue through appeals rather than switching.

Current Treatment Options for Pediatric NF1

FDA-Approved Systemic Therapies

Koselugo (selumetinib)

  • Indication: Pediatric patients ≥2 years with NF1 and symptomatic, inoperable plexiform neurofibromas
  • Mechanism: MEK1/2 inhibitor, oral capsules (10mg, 25mg)
  • Dosing: 25 mg/m² twice daily with monitoring for cardiac and ocular toxicity
  • Coverage status: Prior authorization required but generally covered when criteria met

Mirdametinib (Gomekli)

  • New approval: February 2025 for both adults and pediatric NF1 patients
  • Advantage: May have lower adverse event rates compared to selumetinib
  • Coverage status: Still being added to formularies; check current Blue Shield status

Non-Pharmacologic Options

  • Surgery: First-line for operable tumors threatening critical structures
  • Clinical trials: Available at major California centers (UCSF, Children's Hospital Los Angeles, Stanford)
  • Supportive care: Pain management, physical therapy, psychological support

Blue Cross Blue Shield Coverage Requirements

Coverage at a Glance

Requirement What It Means Where to Find It Source
Prior Authorization PA required for all Koselugo prescriptions Blue Shield PA Policy List Blue Shield CA
Formulary Status Specialty tier, not standard formulary Drug Formulary Search Blue Shield CA
Age Limits Typically ≥2 years per FDA labeling FDA prescribing information FDA
Diagnosis Codes NF1 with plexiform neurofibromas (ICD-10: Q85.01) Medical necessity documentation Clinical
Baseline Testing LVEF assessment, ophthalmologic exam required FDA safety requirements FDA Label

Medical Necessity Criteria

Blue Cross Blue Shield typically requires documentation of:

  1. Confirmed NF1 diagnosis (genetic testing or clinical criteria)
  2. Imaging evidence of plexiform neurofibromas
  3. Symptomatic disease (pain, functional impairment, disfigurement)
  4. Inoperability (surgeon's assessment that complete resection isn't feasible)
  5. Baseline safety assessments (echocardiogram, eye exam)
  6. Specialty provider involvement (pediatric oncology, genetics, or neurology)

Step-by-Step: Fastest Path to Approval

1. Confirm Current Coverage (Patient/Family)

  • Action: Call Blue Shield member services at (888) 266-8080
  • Ask for: Current formulary status of Koselugo, PA requirements, preferred specialty pharmacy
  • Timeline: 10-15 minutes
  • Document: Plan ID, group number, effective dates

2. Gather Required Documentation (Clinic)

  • Medical records showing NF1 diagnosis and tumor characteristics
  • Imaging reports (MRI) demonstrating inoperable plexiform neurofibromas
  • Baseline testing results (LVEF, ophthalmologic exam)
  • Functional assessments documenting symptoms and impact
  • Timeline: 1-2 weeks to coordinate

3. Submit Prior Authorization (Provider)

  • Method: Blue Shield provider portal or authorization forms
  • Include: Complete medical necessity letter with all supporting documentation
  • Timeline: Submit within 24-48 hours of gathering documents
  • Follow-up: Track status through provider portal

4. Await Determination (10-14 business days)

  • Standard review: 10 business days for non-urgent requests
  • Expedited review: 72 hours if medically urgent (provider must justify)
  • No response: Counts as denial after deadline passes

5. If Approved: Coordinate Fulfillment

  • Specialty pharmacy: Blue Shield will designate preferred provider
  • Patient education: Review administration, monitoring, side effects
  • Follow-up: Schedule required monitoring appointments

6. If Denied: Immediate Appeal (Within 30 Days)

  • File internal appeal with Blue Shield
  • Request peer-to-peer review with medical director
  • Prepare for IMR if internal appeal fails

Exception Strategy for Non-Formulary Status

If Koselugo is not on your Blue Shield formulary, request a formulary exception based on:

Medical Necessity Arguments

  1. No therapeutic alternatives for FDA-approved indication
  2. First-line therapy per pediatric oncology guidelines
  3. Contraindications to other MEK inhibitors (if applicable)
  4. Clinical trial evidence supporting efficacy

Required Documentation

  • Letter of medical necessity from pediatric specialist
  • FDA labeling highlighting unique indication
  • Peer-reviewed studies demonstrating efficacy
  • Cost-effectiveness data (if available from manufacturer)
Tip: Counterforce Health can help draft evidence-based exception requests that align with your plan's specific criteria and increase approval odds.

Appeals Playbook for California

Internal Appeal Process

Timeline: 30 calendar days from denial notice Method: Written appeal to Blue Shield utilization management Required documents:

  • Original denial letter
  • Additional medical records
  • Updated medical necessity letter
  • Peer-reviewed literature supporting use

Independent Medical Review (IMR)

California offers robust external appeal rights through the Department of Managed Health Care (DMHC):

Eligibility: After internal appeal denial or 30-day non-response Timeline: Must request within 30 days of internal appeal decision Process: Independent physician reviewers evaluate medical necessity Success rate: Approximately 10-11% for specialty drug appeals Cost: No fee to patient Decision: Binding on insurance plan

How to file IMR:

  1. Complete online application or call (888) 466-2219
  2. Submit medical records and denial correspondence
  3. Await assignment to independent review organization
  4. Decision within 30-45 days (expedited: 72 hours for urgent cases)

DMHC Help Center Resources

  • Phone: (888) 466-2219
  • Website: healthhelp.ca.gov
  • Services: IMR applications, complaint filing, plan compliance issues
  • Languages: Assistance available in multiple languages

Common Denial Reasons & Solutions

Denial Reason Solution Strategy Required Documentation
"Not medically necessary" Emphasize FDA approval for specific indication FDA labeling, clinical trial data, specialist letter
"Experimental/investigational" Reference 2020 FDA approval FDA approval letter, prescribing information
"Missing baseline testing" Complete required safety assessments Echocardiogram results, ophthalmology report
"Age restrictions" Confirm patient meets FDA criteria Birth certificate, medical records
"Alternative therapies available" Document lack of effective alternatives Literature review, specialist assessment
"Quantity limits exceeded" Justify dosing based on body surface area Growth charts, dosing calculations

Scripts for Common Scenarios

Patient calling Blue Shield: "I'm calling about prior authorization for Koselugo for my child with neurofibromatosis. This is the only FDA-approved treatment for their condition. Can you tell me the current status and what additional information is needed?"

Provider requesting peer-to-peer: "I'm requesting a peer-to-peer review for a pediatric patient with NF1 and symptomatic plexiform neurofibromas. Koselugo is the only FDA-approved therapy for this indication. When can we schedule the clinical review?"

Costs & Patient Support Programs

Manufacturer Support

AstraZeneca Koselugo Patient Support Program

  • Copay assistance: May reduce out-of-pocket costs for eligible patients
  • Prior authorization support: Dedicated team to assist with appeals
  • Contact: Available through prescribing physician

Financial Assistance Options

  • Children's Tumor Foundation: Grants for NF1 treatment costs
  • National Organization for Rare Disorders (NORD): Patient assistance programs
  • HealthWell Foundation: Copay assistance for rare disease medications
  • State programs: California may have additional support through Medi-Cal or other programs
From our advocates: "Families often overlook manufacturer patient assistance programs. One family we worked with reduced their monthly Koselugo copay from $1,200 to $50 through AstraZeneca's program, even with commercial insurance. Always ask your specialty pharmacy about available programs."

When to Escalate

If standard appeals fail, consider these additional resources:

State Regulators

  • DMHC Help Center: (888) 466-2219 for HMO/managed care plans
  • California Department of Insurance: (800) 927-4357 for other health policies
  • Covered California: If enrolled through state exchange
  • Health Consumer Alliance: Free assistance for California residents
  • Counterforce Health: Specialized support for complex medication appeals
  • Legal aid organizations: May assist with insurance disputes

FAQ

How long does Blue Cross Blue Shield PA take in California? Standard prior authorization decisions are made within 10 business days. Expedited reviews (for urgent medical situations) are completed within 72 hours.

What if Koselugo is non-formulary on my Blue Shield plan? Request a formulary exception through your doctor. Provide medical necessity documentation emphasizing that Koselugo is the only FDA-approved treatment for pediatric NF1 plexiform neurofibromas.

Can I request an expedited appeal if my child's condition is worsening? Yes. If the delay in treatment poses immediate health risks, your doctor can request expedited review at both the internal appeal and IMR levels.

Does step therapy apply to Koselugo? Generally no. Since Koselugo is the first and only FDA-approved systemic therapy for this specific indication, step therapy requirements typically don't apply.

What happens if we move to another state during treatment? As of January 2026, Blue Cross plans will honor existing prior authorizations for 90 days when you transfer between in-network providers, giving you time to establish care and renew authorization.

How much does Koselugo cost without insurance? Cash prices range from approximately $2,651 for 28×10mg capsules to $6,617 for 28×25mg capsules. Annual costs can exceed $250,000 depending on the patient's body surface area and dosing requirements.

Are there clinical trials available in California? Yes. Major medical centers including UCSF Benioff Children's Hospital, Children's Hospital Los Angeles, and Stanford offer clinical trials for NF1 treatments. Ask your specialist about current studies.

What should I do if Blue Shield denies coverage after IMR? IMR decisions are binding on insurance plans in California. If Blue Shield doesn't comply with a favorable IMR decision, contact the DMHC Help Center immediately at (888) 466-2219.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Insurance coverage varies by plan and individual circumstances. Always consult with your healthcare provider and insurance company for personalized guidance. For assistance with complex appeals, consider working with specialized services like Counterforce Health, which helps families navigate insurance denials with evidence-based appeal strategies.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.